Form SC 13G - Statement of Beneficial Ownership by Certain Investors

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

SCHEDULE 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

Under the Securities Exchange Act of 1934

(Amendment No. )

 

 

CIDARA THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.0001

par value per share

(Title of Class of Securities)

171757206

(CUSIP Number)

July 18, 2024

(Date of Event Which Requires Filing of This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐

Rule 13d-1(b)

 

☒

Rule 13d-1(c)

 

☐

Rule 13d-1(d)

 

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

---

CUSIP No. 171757206		13G		Page 2 of 6 Pages

 

1		Names of Reporting Persons    BCLS Fund III Investments, LP
2		Check the Appropriate Box if a Member of a Group    (a) ☐  (b) ☐
3		SEC Use Only
4		Citizenship or Place of Organization    Delaware

Number of Shares  Beneficially  Owned by Each Reporting Person With				5		Sole Voting Power    0 shares of Common Stock
				6		Shared Voting Power    703,080 shares of Common Stock
				7		Sole Dispositive Power    0 shares of Common Stock
				8		Shared Dispositive Power    703,080 shares of Common Stock

9		Aggregate Amount Beneficially Owned by Each Reporting Person    703,080 shares of Common Stock
10		Check if the Aggregate Amount in Row (9) Excludes Certain Shares    ☐
11		Percent of Class Represented by Amount in Row 9    9.99%
12		Type of Reporting Person    PN

---

CUSIP No. 171757206		13G		Page 3 of 6 Pages

 

Item 1(a)

Name of Issuer

The name of the issuer to which this filing on Schedule 13G relates is Cidara Therapeutics, Inc. (the “Issuer”).

 

Item 1(b)

Address of Issuer’s Principal Executive Offices

The principal executive offices of the Issuer are located at 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121.

 

Item 2(a)

Name of Person Filing

This Schedule 13G is being filed by BCLS Fund III Investments, LP, a Delaware limited partnership (the “Reporting Person”).

Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company (“BCLSI”), is the manager of Bain Capital Life Sciences III General Partner, LLC, a Delaware limited liability company (“BCLS Fund III GP”), which is the general partner of Bain Capital Life Sciences Fund III, L.P., a Delaware limited partnership (“BCLS Fund III”), which is the managing member of BCLS Fund III Investments GP, LLC, a Delaware limited liability company (together with the Reporting Person, BCLSI, BCLS Fund III GP and BCLS Fund III, the “Bain Capital Life Sciences Entities”), which is the general partner of the Reporting Person. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person.

 

Item 2(b)

Address of Principal Business Office or, if None, Residence

The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116.

 

Item 2(c)

Citizenship

Each of the Bain Capital Life Sciences Entities is organized under the laws of the State of Delaware.

 

Item 2(d)

Title of Class of Securities

The class of securities of the Issuer to which this Schedule 13G relates is Common Stock, $0.0001 par value per share (“Common Stock”).

 

Item 2(e)

CUSIP Number

The CUSIP number of the Common Stock is 171757206.

 

Item 3

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a

 

(a)		☐		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)		☐		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)		☐		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)		☐		Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)		☐		An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)		☐		An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

---

CUSIP No. 171757206		13G		Page 4 of 6 Pages

 

(g)		☐		A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)		☐		A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)		☐		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
(j)		☐		A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k)		☐		Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

 

Item 4

Ownership

(a) Amount beneficially owned:

As of the date hereof, the Reporting Person holds 703,080 shares of Common Stock, representing 9.99% of the outstanding shares of Common Stock.

In addition, the Reporting Person holds 89,956 shares of the Issuer’s Series A Convertible Voting Preferred Stock, which, as of the date hereof, are eligible for conversion into an aggregate of 6,296,920 shares of Common Stock, subject to a conversion blocker which prohibits the conversion of any shares of Series A Convertible Voting Preferred Stock, if, as a result of such conversion, the Reporting Person would, together with its attribution parties, beneficially own in excess of 9.99% of outstanding shares of Common Stock immediately after giving effect to such conversion.

The percentage of the outstanding shares of Common Stock held by the Reporting Person is based on 7,038,241 shares of Common Stock issued and outstanding as of July 19, 2024, as reported by the Issuer in its Registration Statement on Form S-1, filed with the Securities and Exchange Commission on July 19, 2024.

(b) Percent of class:

See Item 4(a) hereof.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0 shares of Common Stock

(ii) Shared power to vote or to direct the vote:

703,080 shares of Common Stock

(iii) Sole power to dispose or to direct the disposition of:

0 shares of Common Stock

(iv) Shared power to dispose or to direct the disposition of:

703,080 shares of Common Stock

---

CUSIP No. 171757206		13G		Page 5 of 6 Pages

 

Item 5

Ownership of Five Percent or Less of a Class

Not applicable.

 

Item 6

Ownership of More Than Five Percent on Behalf of Another Person

Not applicable.

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

 

Item 8

Identification and Classification of Members of the Group

Not applicable.

 

Item 9

Notice of Dissolution of Group

Not applicable.

 

Item 10

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

---

CUSIP No. 171757206		13G		Page 6 of 6 Pages

 

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information in this statement is true, complete and correct.

 

Dated: July 29, 2024		BCLS Fund III Investments, LP
		By:		BCLS Fund III Investments GP, LLC,
				its general partner
		By:		Bain Capital Life Sciences Fund III, L.P.,
				its member
		By:		Bain Capital Life Sciences III General Partner, LLC,
				its general partner
		By:		Bain Capital Life Sciences Investors, LLC,
				its manager
		By:		/s/ Andrew Hack
				Name:		Andrew Hack
				Title:		Partner

---